Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review

Abstract Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete,...

Full description

Saved in:
Bibliographic Details
Published inMedical principles and practice Vol. 33; no. 2; pp. 102 - 111
Main Authors Okwor, Chika Juliet, Okwor, Vitalis Chukwuemeka, Meka, Ijeoma A., Emedoh, Andrew Emeka, Nweke, Martin
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.04.2024
Subjects
Online AccessGet full text
ISSN1011-7571
1423-0151
1423-0151
DOI10.1159/000535965

Cover

Abstract Abstract Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. Results: We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042–1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917–1.630). Conclusions: Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence. Highlights of the StudySurvivorship of prostate cancer (PCa) is arguably the most essential consideration when planning prostatectomy as a definitive treatment for PCa.The usefulness of total prostate-specific antigen (PSA) as a determinant of survivorship of PCa is reported with ambivalence.The study demonstrated that the sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged.
AbstractList [...]there is an urgent need to ascertain the odds for treatment success (BCR and mortality) with RP [6, 7]. [...]our study aimed to evaluate the relationship between pre-operative tPSA and survivorship of PCa following RP. [...]studies were considered if one or more of the dependent variables were linked to pre-operative tPSA. [...]to be eligible for inclusion in the meta-analysis study, we had to report adjusted HR and their corresponding 95% confidence intervals derived from multivariate regression models.
This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042-1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917-1.630). Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence.
Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. Results: We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042–1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917–1.630). Conclusions: Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence.
This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa).OBJECTIVEThis review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa).Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity.METHODSData sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity.We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042-1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917-1.630).RESULTSWe found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042-1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917-1.630).Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence.CONCLUSIONSBiochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence.
Abstract Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. Results: We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042–1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917–1.630). Conclusions: Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence. Highlights of the StudySurvivorship of prostate cancer (PCa) is arguably the most essential consideration when planning prostatectomy as a definitive treatment for PCa.The usefulness of total prostate-specific antigen (PSA) as a determinant of survivorship of PCa is reported with ambivalence.The study demonstrated that the sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged.
Author Emedoh, Andrew Emeka
Okwor, Chika Juliet
Nweke, Martin
Okwor, Vitalis Chukwuemeka
Meka, Ijeoma A.
Author_xml – sequence: 1
  givenname: Chika Juliet
  surname: Okwor
  fullname: Okwor, Chika Juliet
– sequence: 2
  givenname: Vitalis Chukwuemeka
  surname: Okwor
  fullname: Okwor, Vitalis Chukwuemeka
– sequence: 3
  givenname: Ijeoma A.
  surname: Meka
  fullname: Meka, Ijeoma A.
  email: *Ijeoma A. Meka, ijeoma.meka@unn.edu.ng
– sequence: 4
  givenname: Andrew Emeka
  surname: Emedoh
  fullname: Emedoh, Andrew Emeka
– sequence: 5
  givenname: Martin
  surname: Nweke
  fullname: Nweke, Martin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38142683$$D View this record in MEDLINE/PubMed
BookMark eNptkk1v1DAQhi1URD_gwB0hS1zgELDjOHF6QatV-ZCKuuqWs-V1JluXrB1sJ6v9K_21uNolFMTFY71-9M54Zk7RkXUWEHpJyXtKef2BEMIZr0v-BJ3QImcZoZwepTuhNKt4RY_RaQh3CROMkWfomImElYKdoPtZCE4bFY2zeAVxC2DxwkN21YNP6gj4xkXVJc2FqCJkyx60aY3GMxvNOtHKNng5-NGMzodb02PXTjSeK6vB49Z1ndsau8bXqjH6kZ-ObrM7xzO83IUIm5RS42sYDWyfo6et6gK8OMQz9P3Txc38S3Z59fnrfHaZ6UKQmFHWtLlgDSUESk7qoqhywYGvdMmLBtKpGCVtpfOW1aysabHiiuRJqHgBpGVn6OPetx9WG2g02OhVJ3tvNsrvpFNG_v1iza1cu1FSSuqyqvPk8Pbg4N3PAUKUGxM0dJ2y4IYg85rwSlAmyoS--Qe9c4O36X-SkaLkORVcJOr145KmWn7PLQHv9oBObQwe2gmhRD7shJx24k_KH8qvwU_kt8ViT8i-eejCq_9SB5NfYFi_oQ
ContentType Journal Article
Copyright 2023 The Author(s). Published by S. Karger AG, Basel
2023 The Author(s). Published by S. Karger AG, Basel.
2023 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content
2023 The Author(s). Published by S. Karger AG, Basel 2023
Copyright_xml – notice: 2023 The Author(s). Published by S. Karger AG, Basel
– notice: 2023 The Author(s). Published by S. Karger AG, Basel.
– notice: 2023 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content
– notice: 2023 The Author(s). Published by S. Karger AG, Basel 2023
DBID M--
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOI 10.1159/000535965
DatabaseName Karger Open Access Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE
CrossRef
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: M--
  name: Karger Open Access Journals
  url: https://www.karger.com/OpenAccess
  sourceTypes:
    Enrichment Source
    Publisher
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate TPSA Levels and Survival after Prostatectomy
EISSN 1423-0151
EndPage 111
ExternalDocumentID PMC11096792
38142683
10_1159_000535965
535965
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
0R~
0~B
30W
326
36B
3O.
3V.
4.4
53G
5GY
7X7
88E
8FI
8FJ
8UI
AAWTL
AAYIC
ABPAZ
ABUWG
ACGFS
ADBBV
AENEX
AEYAO
AFKRA
AHMBA
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZPMC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CS3
CYUIP
DU5
E0A
E3Z
EBS
EMB
EMOBN
F5P
FB.
FYUFA
GROUPED_DOAJ
HMCUK
HYE
HZ~
IAO
IHR
KUZGX
M--
M1P
MK0
O1H
O9-
OK1
P2P
PQQKQ
PROAC
PSQYO
RKO
RNS
RPM
SV3
UJ6
UKHRP
AAYXX
ABBTS
ABWCG
ACQXL
ADAGL
AFJJK
AFSIO
AHFRZ
AIOBO
CAG
CITATION
COF
DIK
EJD
ITC
PHGZM
PHGZT
PJZUB
PPXIY
RIG
RXVBD
TR2
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c480t-13df283d100e6509447285e5bc654dec65a310f7c2f3936914b5a02f7c754e0f3
IEDL.DBID 7X7
ISSN 1011-7571
1423-0151
IngestDate Thu Aug 21 18:35:35 EDT 2025
Fri Sep 05 11:16:26 EDT 2025
Fri Jul 25 04:10:44 EDT 2025
Sun May 18 01:30:14 EDT 2025
Tue Aug 05 12:09:27 EDT 2025
Thu Aug 29 12:04:27 EDT 2024
Sat Aug 31 21:00:32 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Prostatectomy
Prognosis
Prostate-specific antigen
Survival
Language English
License This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
https://creativecommons.org/licenses/by-nc/4.0
2023 The Author(s). Published by S. Karger AG, Basel.
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c480t-13df283d100e6509447285e5bc654dec65a310f7c2f3936914b5a02f7c754e0f3
Notes ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
OpenAccessLink https://karger.com/doi/10.1159/000535965
PMID 38142683
PQID 3046521858
PQPubID 2047984
PageCount 10
ParticipantIDs crossref_primary_10_1159_000535965
proquest_journals_3046521858
proquest_miscellaneous_2905781386
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11096792
pubmed_primary_38142683
karger_primary_535965
PublicationCentury 2000
PublicationDate 2024-04-01
PublicationDateYYYYMMDD 2024-04-01
PublicationDate_xml – month: 04
  year: 2024
  text: 2024-04-01
  day: 01
PublicationDecade 2020
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Switzerland
– name: Basel
PublicationTitle Medical principles and practice
PublicationTitleAlternate Med Princ Pract
PublicationYear 2024
Publisher S. Karger AG
Publisher_xml – name: S. Karger AG
References Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9. Erratum in: BJU Int. 2013;111(3):524.
Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJr, DotanZA, DiBlasio CJ, . Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23(28):7005–12.
Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, . Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States. Infect Agent Cancer. 2009;S2(Suppl 1):4.
Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2023.
Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, . Contemporary pathological stage distribution after radical prostatectomy in North American high-risk prostate cancer patients. Clin Genitourin Cancer. 2022;20(5):e380–9.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, . Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.
Nwagha T, Nweke M. Stratification of risk factors of lung cancer-associated venous thromboembolism and determining the critical point for preemptive intervention: a systematic review with meta-analysis. Clin Med Insights Oncol. 2023;17:11795549231175221.
Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, . Biochemical recurrence after radical prostatectomy: what does it mean. Int Braz J Urol. 2018;44(1):14–21.
Lenhard W, Lenhard A. Calculation of effect sizes. Bibergau (Germany): Psyhometrica; 2015. http://www.psychometrica.de/effect_size.htlm.
Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, . Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905–15.
Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5(1):7–13.
Vickers AJ, Eastham JA, Scardino PT, Lilja H. The memorial sloan kettering cancer center recommendations for prostate cancer screening. Urology. 2016;91:12–8.
Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, . Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. Prostate. 2022;82(6):687–94.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.
Würnschimmel C, Pose RM, Wenzel M, Tian Z, Incesu RB, Karakiewicz P, . Validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence, metastasis, and cancer-specific mortality after radical prostatectomy in a European cohort. Eur Urol. 2021;80(4):400–4.
McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, . Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int. 2012;109(12):1764–9.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, , editors. Cochrane Handbook for systematic reviews of interventions version 6.3. Cochrane; 2022. Available from: www.training.cochrane.org/handbook (updated February 2022).
D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7.
Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. Prostate. 2023;83(7):695–700.
Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of the type and number of d’amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. Cent Eur J Urol. 2023;76(2):104–8.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
Morgan SC, Morton GC, Berlin A, Cheung P, Chung P, Ménard C, . Current topics in radiotherapy for genitourinary cancers: consensus statements of the Genitourinary Radiation Oncologists of Canada. Can Urol Assoc J. 2020;14(11):E588–93.
Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl. 2018;20(6):551–4.
Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, . The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol. 2013;109(2):204–10.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, . Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015;22(4):362–6.
Morka N, Simpson BS, Ball R, Freeman A, Kirkham A, Kelly D, . Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy. BMJ Open. 2021;11(5):e047664.
Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039–46.
Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’Amico risk classification of prostate cancer. Adult Urol. 2007;70(5):931–5.
Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, . The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels. Prostate. 2015;75(10):1034–42.
Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cut point for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365–9.
Ikuemonisan J, Lediju O, Togun A, Adejoro O. Association between preoperative prostate-specific antigen levels and mortality in high- and intermediate-grade prostate cancer patients who received radical prostatectomy: findings from the SEER database. Prostate Int. 2021;9(2):72–7.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester, UK: John Wiley & Sons. Ltd; 2009.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.
Ferraro S, Biganzoli EM. The clinical value of assessing the intermethod bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med. 2021;60(2):149–51.
Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer. 2010;127(12):2893–917.
Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, . Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a pre-operative serum prostate-specific antigen level > or = 50 ng/mL. Cancer. 2008;113(7):1544–51.
Nweke M, Ukwuoma M, Adiuku-Brown AC, Ugwu P, Nseka E. Characterization and stratification of the correlates of postpartum depression in sub-Saharan Africa: a systematic review with meta-analysis. Womens Health. 2022;18:17455057221118773.
Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, . The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Education Inf. 2018;34(4):285–91.
Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, . Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618–25.
References_xml – reference: Vickers AJ, Eastham JA, Scardino PT, Lilja H. The memorial sloan kettering cancer center recommendations for prostate cancer screening. Urology. 2016;91:12–8.
– reference: Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, . Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905–15.
– reference: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
– reference: D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7.
– reference: Ferraro S, Biganzoli EM. The clinical value of assessing the intermethod bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med. 2021;60(2):149–51.
– reference: Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039–46.
– reference: Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. Prostate. 2023;83(7):695–700.
– reference: Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester, UK: John Wiley & Sons. Ltd; 2009.
– reference: Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
– reference: Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.
– reference: Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, . Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015;22(4):362–6.
– reference: Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2023.
– reference: Ikuemonisan J, Lediju O, Togun A, Adejoro O. Association between preoperative prostate-specific antigen levels and mortality in high- and intermediate-grade prostate cancer patients who received radical prostatectomy: findings from the SEER database. Prostate Int. 2021;9(2):72–7.
– reference: Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, . Biochemical recurrence after radical prostatectomy: what does it mean. Int Braz J Urol. 2018;44(1):14–21.
– reference: Lenhard W, Lenhard A. Calculation of effect sizes. Bibergau (Germany): Psyhometrica; 2015. http://www.psychometrica.de/effect_size.htlm.
– reference: Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, . Contemporary pathological stage distribution after radical prostatectomy in North American high-risk prostate cancer patients. Clin Genitourin Cancer. 2022;20(5):e380–9.
– reference: Morka N, Simpson BS, Ball R, Freeman A, Kirkham A, Kelly D, . Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy. BMJ Open. 2021;11(5):e047664.
– reference: Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJr, DotanZA, DiBlasio CJ, . Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23(28):7005–12.
– reference: McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, . Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int. 2012;109(12):1764–9.
– reference: Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, . Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.
– reference: Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, . Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618–25.
– reference: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, , editors. Cochrane Handbook for systematic reviews of interventions version 6.3. Cochrane; 2022. Available from: www.training.cochrane.org/handbook (updated February 2022).
– reference: Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, . Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. Prostate. 2022;82(6):687–94.
– reference: Nwagha T, Nweke M. Stratification of risk factors of lung cancer-associated venous thromboembolism and determining the critical point for preemptive intervention: a systematic review with meta-analysis. Clin Med Insights Oncol. 2023;17:11795549231175221.
– reference: Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.
– reference: Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9. Erratum in: BJU Int. 2013;111(3):524.
– reference: Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, . Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States. Infect Agent Cancer. 2009;S2(Suppl 1):4.
– reference: Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of the type and number of d’amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. Cent Eur J Urol. 2023;76(2):104–8.
– reference: Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, . The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol. 2013;109(2):204–10.
– reference: Nweke M, Ukwuoma M, Adiuku-Brown AC, Ugwu P, Nseka E. Characterization and stratification of the correlates of postpartum depression in sub-Saharan Africa: a systematic review with meta-analysis. Womens Health. 2022;18:17455057221118773.
– reference: Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl. 2018;20(6):551–4.
– reference: Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’Amico risk classification of prostate cancer. Adult Urol. 2007;70(5):931–5.
– reference: Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, . The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels. Prostate. 2015;75(10):1034–42.
– reference: Würnschimmel C, Pose RM, Wenzel M, Tian Z, Incesu RB, Karakiewicz P, . Validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence, metastasis, and cancer-specific mortality after radical prostatectomy in a European cohort. Eur Urol. 2021;80(4):400–4.
– reference: Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5(1):7–13.
– reference: Morgan SC, Morton GC, Berlin A, Cheung P, Chung P, Ménard C, . Current topics in radiotherapy for genitourinary cancers: consensus statements of the Genitourinary Radiation Oncologists of Canada. Can Urol Assoc J. 2020;14(11):E588–93.
– reference: Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, . The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Education Inf. 2018;34(4):285–91.
– reference: Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cut point for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365–9.
– reference: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer. 2010;127(12):2893–917.
– reference: Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, . Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a pre-operative serum prostate-specific antigen level > or = 50 ng/mL. Cancer. 2008;113(7):1544–51.
– reference: D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.
SSID ssj0008330
Score 2.3352385
SecondaryResourceType review_article
Snippet Abstract Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship...
Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of...
This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer...
[...]there is an urgent need to ascertain the odds for treatment success (BCR and mortality) with RP [6, 7]. [...]our study aimed to evaluate the relationship...
SourceID pubmedcentral
proquest
pubmed
crossref
karger
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 102
SubjectTerms Antigens
Data analysis
Humans
Male
Medical prognosis
Medical Subject Headings-MeSH
Mortality
Multivariate analysis
Neoplasm Recurrence, Local
Preoperative Period
Prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy
Prostatic Neoplasms - blood
Prostatic Neoplasms - mortality
Prostatic Neoplasms - surgery
Risk assessment
Survivor
Systematic Review
SummonAdditionalLinks – databaseName: Karger Open Access Journals
  dbid: M--
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3fT9swED4xQBUvaPwYZGPIIF6tJbGduLxVaFWFVFYNkPoWxYmtoWlJVVoQ_wp_7c52alG0veThzpGV3Nn32Xf-DHAhshKBasUoU2VNudYpVcxy47EsVhiucqPtfsf4Jhvd8-upmHb7HfYszG9b_-yoUQO3AAbcb56HpJ-JD7CFATe3xXtjSsOcKxnzvANJQrGDpOMQWnt1B3oYnjAiSbYWhLZ9n_-CmO8rJd-EnuFH2O0wIxl4I-_Bhm72oTfusuIH8PrmH5Ou8IpM5pr-mGlP7E3uWgTZKGvdASLqbp03DxUZNAtLx0nKpia3S5w2nlpX10xaE1qTK-sZc2LQZdpnDHXkZ-myO6FFtWj_vFySAbkNvNDEJx0O4X74_e5qRLs7F2jFZWxvpq8NIo46iWPtyPV4nkqhhaoywWuNzxIBocmr1DB7F2DClSjjFAW54Do27BNsNm2jjwG_lzNTx2lZcVxz6VoapVWlLIF-jgtvFsH5ygjFzFNrFG5JIvpFMFoEh948oclKfvJOPp5MvKqY1QbVK2MW3aB8LGwSGNGKFDKCs6DG4WRzJGWj2-VjkfYRwMqEySyCI2_70MPKeyKQa14RGliq7nVN8_DLUXZbXtcs76ef__M5X2AnRbTkS4JOYHMxX-qviHYW6tQ5-l-Wkfry
  priority: 102
  providerName: Karger AG
Title Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review
URI https://karger.com/doi/10.1159/000535965
https://www.ncbi.nlm.nih.gov/pubmed/38142683
https://www.proquest.com/docview/3046521858
https://www.proquest.com/docview/2905781386
https://pubmed.ncbi.nlm.nih.gov/PMC11096792
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagRagXVKCUpWVlEFerSWwnWS5oW1oV0JZVH9LeovglKkS83QeIv8Kv7fixZlshLpZiW7KTGXs-eybfIPSOly0AVUkJFa0iTOuCCOq48WiZCTBXldHuvmN0Vp5esc8TPokXbvMYVrnaE_1Grax0d-QHzoMHpqbm9YfpDXFZo5x3NabQeIg2c0AiLnVDNUkHLkAXNLAR5DmBYfPILAQW_CAQmwycTVmzR4--u_Dr2b_Q5v2gyTUrdLKNnkT4iIdB3k_RA909Q49H0UH-HP1Z-9w4xmDh8UyTr1MdOL7xpQW8DXXW_0tEfAJ6cy3xsFs4Zk7cdgpfLGEH-Wl9iDO2JvXGR05JZtiA9thfYPXweesdPamHXNgfv9_jIb5IFNE4-B920NXJ8eXRKYnpF4hkdeaS1CsD4EPlWaY9zx6ripprLmTJmdJQtoANTSULQ11awJwJ3mYFVFSc6czQF2ijs51-ieB9GTUqK1rJ4PilVW2EFlI4Lv0KzuC0h96uhNBMA8tG408nfNAkSfXQThBP6rKq379XPxqPQ1MzVQaaV8Js4vqcN3-1qYfepGZYWc5d0nbaLudNMQAsW-e0LntoN8g-jQA4B6CNm3h9RytSB8fafbelu_7m2bsdxWtZDYpX_5_XHtoqAD-FIKF9tLGYLfVrwD8L0fdK3kebh8dn43N4-vjpS9_fJUA5IuQWuVoKsA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VgqAXxKPQLQUMgqPVxI8ki4TQqlBtabes6FbaW5qHLaqqyXYfVP0r_Ah-IzNxErYV4tZLDraVxJqx5xvP-BuAdzpIEKhmkss0ybkyRvBUEjeeDLwUzVVoDZ13DA6D_rH6OtbjFfjd3IWhtMpmT6w26rzM6Ix8myJ4aGoiHX2aXHCqGkXR1aaEhlOLfXN1iS7b7OPeZ5TveyF2v4x2-ryuKsAzFXlUez23aFNz3_NMRR-nQhFpo9Ms0Co3-EwQ8tgwE1ZStTtfpTrxBDaEWhnPSnzvHbirKMSI6ycctw4eohnp2A98n-M0_ZrJCBHDtiNS6ZINW7J_984o3Xv6L3R7M0lzyertPoKHNVxlPadfj2HFFE_g_qAOyD-FX0viZXXOFxtODf82MY5TnI1KxPfYVlZ3l3hV8N6eZqxXzIkJlCVFzo4WuGP9LKuUalbadjTbIaWcMovaWl6ilWXfkyqw1I7I5uX51QfWY0ctJTVz8Y51OL4VwTyD1aIszAbgfJW0uSeSTKG7Z_LIpibNUuLuD9Hnlx142wghnjhWj7jyhnQ3biXVgXUnnnZI0751o30wHLqueJJb7G6EGdf7wSz-q70deNN240qm8ExSmHIxi0UXsXPkyyjowHMn-_YLiKsQStGPR9e0oh1ALOHXe4rTHxVbOFHKBmFXbP7_v17Dg_5ocBAf7B3uv4A1gdjNJShtwep8ujAvEXvN01eVwjM4ue0V9gfNjEGD
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwEB2VFlW8IC4FFgoYBI_RJnYuXqQKLW1XLWWXqNtKfUvj2BYIkYS9UPVX-CS-inHshG2FeOtLHmxrk82MfY4z4zMAb6I4R6JaMI-JXHqhUtQTzGjjsdgXCFeJVuZ7x3gSH5yGH8-iszX43Z6FMWmV7ZrYLNSyKsw38r6J4CHU8Ij3tUuLSPdG7-sfnqkgZSKtbTmN3JVZkDuN3Jg75HGkLi9wOzffOdxD27-ldLR_snvguYoDXhFy39RllxrxVga-rxppuTChPFKRKOIolAqvOdIhnRRUM1MJLwhFlPsUG5IoVL5m-Lu3YCNB1MeN4MaH_Ul63OECZ8xqIwSBhy8hcDpHyCf6VmZlYBBuBR1vfzPJ4LN_cd_rKZwrmDi6B3cdmSVD6333YU2VD2Bz7ML1D-HXivGJywgj6Ux5n2tlFcfJSYXsH9uq5mSTN61VkyRIhvhq0bdJXkoyXeJ69rNqEq5JpbvRZNe47Ixo9OXqAjGYHOdN2KkbUSyq75fvyJBMO8FqYqMhW3B6I6Z5BOtlVaongP83ZFr6NC9C3AwqybVQohBG2T9JOGc9eN0aIaut5kfW7JWiQdZZqgdb1jzdkLZ9-1r7OE1tV1ZLjd2tMTO3Wsyzv77dg1ddN85zE7zJS1Ut5xkdILPmAeNxDx5b23d3QNaFRMs8OL_iFd0AoyF-taf8-qXREjeCs3EyoE___1wvYRNnW_bpcHL0DO5QJHY2e2kb1hezpXqOxGwhXjiPJ3B-05PsD_j4TF4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+Pre-Operative+Total+Prostate-Specific+Antigen+and+Survivorship+of+Prostate+Cancer+following+Radical+Prostatectomy%3A+A+Systematic+Review&rft.jtitle=Medical+principles+and+practice&rft.au=Okwor%2C+Chika+Juliet&rft.au=Okwor%2C+Vitalis+Chukwuemeka&rft.au=Meka%2C+Ijeoma+A&rft.au=Emedoh%2C+Andrew+Emeka&rft.date=2024-04-01&rft.issn=1423-0151&rft.eissn=1423-0151&rft.volume=33&rft.issue=2&rft.spage=102&rft_id=info:doi/10.1159%2F000535965&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon